{"result": {"id": "1d6660c5-9e44-41a9-b1fb-f4ff95a148ca", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"PCSK9 Inhibitors and Gene Editing in Cholesterol Management\",\n    \"summary\": \"This community focuses on entities involved in cholesterol management, particularly through PCSK9 inhibitors and gene-editing technologies. Key entities include Inclisiran, MK-0616, PCSK9 protein, and CRISPR-Cas, with relationships highlighting their roles in lowering LDL-C levels and potential for gene therapy. The community's impact is significant due to its potential to revolutionize treatment for hypercholesterolemia and related conditions.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The high impact severity rating reflects the potential of these technologies to significantly improve cardiovascular health outcomes.\",\n    \"findings\": [\n        {\n            \"summary\": \"Inclisiran's approval in China marks a significant milestone\",\n            \"explanation\": \"Inclisiran, a PCSK9 inhibitor, was approved in China in August 2023 for treating adults with primary hypercholesterolemia or mixed dyslipidemia. This approval signifies a major step forward in cholesterol management, offering a new treatment option for patients who cannot achieve target LDL-C levels with statins or cannot tolerate them. [Data: Entities (4432), Relationships (4300)]\"\n        },\n        {\n            \"summary\": \"MK-0616 as a novel oral PCSK9 inhibitor\",\n            \"explanation\": \"MK-0616 represents a breakthrough as an oral PCSK9 inhibitor, showing good efficacy and safety in phase 2b clinical trials. Its development could offer a more convenient treatment option compared to injectable PCSK9 inhibitors, potentially improving patient compliance and outcomes. [Data: Entities (4478), Relationships (4339)]\"\n        },\n        {\n            \"summary\": \"PCSK9's central role in cholesterol metabolism\",\n            \"explanation\": \"PCSK9 is a key protein in cholesterol metabolism, targeted by several inhibitors to lower LDL-C levels. Its inhibition is a proven strategy for improving cardiovascular outcomes, making it a focal point for drug development. [Data: Entities (4423), Relationships (4275, 4276, 4277)]\"\n        },\n        {\n            \"summary\": \"CRISPR-Cas technology's potential in lipid-lowering therapy\",\n            \"explanation\": \"CRISPR-Cas gene-editing technology offers the possibility of permanently inhibiting PCSK9, providing a long-term solution for managing cholesterol levels. This innovative approach could revolutionize treatment paradigms for hypercholesterolemia. [Data: Entities (4481), Relationships (4345, 4346)]\"\n        },\n        {\n            \"summary\": \"Existing PCSK9 inhibitors: Evolocumab, Alirocumab, and Tolezumab\",\n            \"explanation\": \"Evolocumab, Alirocumab, and Tolezumab are established PCSK9 inhibitors used for lowering cholesterol. Their success has paved the way for new inhibitors like Inclisiran and MK-0616, highlighting the ongoing innovation in this therapeutic area. [Data: Entities (4429, 4430, 4431), Relationships (4275, 4276, 4277)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751560420, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 670, "prompt_tokens": 2661, "total_tokens": 3331, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1472}, "prompt_cache_hit_tokens": 1472, "prompt_cache_miss_tokens": 1189}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n4432,英克司兰,英克司兰（Inclisiran）是一种PCSK9抑制剂类药物，主要用于降低胆固醇水平。该药物于2023年8月在中国获批上市，适用于治疗成年人原发性高胆固醇血症和混合型血脂异常。其目标患者群体为经他汀类药物治疗后低密度脂蛋白胆固醇（LDL-C）仍未达到目标值，或无法耐受他汀类药物的患者。通过抑制PCSK9蛋白，英克司兰能有效调节血脂代谢，帮助患者控制胆固醇水平。,2\n4478,MK?0616,\"MK?0616 is a novel oral PCSK9 inhibitor that lowers LDL-C levels by inhibiting PCSK9 binding to LDL-R, with good efficacy and safety shown in phase 2b clinical trials\"\"\",2\n4423,PCSK9,\"**PCSK9 (Proprotein convertase subtilisin/kexin type 9)** is a protein that plays a key role in cholesterol metabolism and is a target for lipid-lowering therapies. It is specifically targeted by **PCSK9 inhibitors**, a class of drugs designed to lower cholesterol levels in patients. These inhibitors work by blocking PCSK9's function, thereby reducing low-density lipoprotein (LDL) cholesterol and improving cardiovascular outcomes. The protein is of significant interest in the development of treatments for hypercholesterolemia and related conditions.\",7\n4481,CRISPR?CAS,\"CRISPR-Cas is a gene-editing technology used to permanently inhibit disease-causing genes, offering new possibilities for lipid-lowering therapy\"\"\",2\n4429,依洛尤单抗,\"Evolocumab, a PCSK9 inhibitor used for lowering cholesterol>\",1\n4430,阿利西尤单抗,\"Alirocumab, a PCSK9 inhibitor used for lowering cholesterol>\",1\n4431,托莱西单抗,\"Tolezumab, a PCSK9 inhibitor used for lowering cholesterol>\",1\n4484,GENE EDITING,,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n4300,英克司兰,中国,英克司兰于2023年8月在中国获批上市,19\n4339,MK?0616,PCSK9,MK?0616 inhibits PCSK9 to lower LDL-C levels,9\n4345,CRISPR?CAS,PCSK9,CRISPR-Cas gene editing can permanently inhibit PCSK9 for lipid-lowering therapy,9\n4275,PCSK9,依洛尤单抗,Evolocumab is a PCSK9 inhibitor that targets PCSK9 to lower cholesterol,8\n4276,PCSK9,阿利西尤单抗,Alirocumab is a PCSK9 inhibitor that targets PCSK9 to lower cholesterol,8\n4277,PCSK9,托莱西单抗,Tolezumab is a PCSK9 inhibitor that targets PCSK9 to lower cholesterol,8\n4346,CRISPR?CAS,GENE EDITING,CRISPR-Cas is used for gene editing to permanently modify PCSK9,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_abb1c943e7d45ef96d346f32b843d9a1fd6a7f636ce34d8ba3174f3fdf4a7d19_v2"}